Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.remnie.2025.500105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between dual-time-point F-FDG PET/CT imaging and pathological grade in hepatocellular carcinoma.
Quant Imaging Med Surg
August 2025
Medical College, Qingdao Binhai University, Qingdao, China.
Background: Dual-time-point (DTP) F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) imaging has been associated with an enhanced diagnostic yield in various malignancies. Nevertheless, there is a lack of data on the use of delayed imaging in patients with hepatocellular carcinoma (HCC). The aim of this study was to investigate the correlation between the semiquantitative parameters of DTP F-FDG PET/CT scan and histological grades of HCC.
View Article and Find Full Text PDFTexture features-guided image reconstruction kernel method forF-FDG delayed PET imaging.
Phys Med Biol
July 2025
Research Center for Medical AI, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, People's Republic of China.
Positron emission tomography (PET) is a crucial imaging technology that is widely used for cancer staging and treatment response assessment. Delayed PET imaging (or dual-time-point imaging) involves a second PET acquisition step approximately 33 min after the initial scan in this study, providing more dynamic biological information, improving lesion detectability, and allowing patients to rest during the scan. However, with increasing time, the number of photons in the second scan decreases, which raises the difficulty of the second PET image reconstruction process.
View Article and Find Full Text PDFDiagnostic efficacy of [F]FDG PET/CT and [F]FDG PET/MRI in preoperative staging of locoregional urinary bladder cancer: a systematic review and Meta-Analysis.
Discov Oncol
July 2025
Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Queen Rania Street, Al Jubeiha, Amman, 11941, Jordan.
Background: This systematic review and meta-analysis aims to evaluate the diagnostic utility of [F]Fluorodeoxyglucose ([F]FDG) PET/CT and [F]FDG PET/MRI in preoperative locoregional staging of bladder cancer (BC).
Methods: A comprehensive search of PubMed and Scopus databases was conducted up to February 26, 2025, to collect and analyze diagnostic accuracy parameters. Statistical analyses, including publication bias assessment, interstudy heterogeneity evaluation, and effect size adjustment, were performed using Stata software, with a significance threshold set at p < 0.
Dual-Time-Point F-FDG PET/CT imaging in the diagnosis of colorectal carcinoma or advanced adenoma in patients with fixed focal colorectal F-FDG uptake.
BMC Cancer
April 2025
Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Background: Fixed focal fluorine 18 fluorodeoxyglucose (F-FDG) uptake in colorectal areas is commonly seen in PET/CT scan and may indicates malignant tumor. This study aims to investigate the diagnostic efficacy of dual-time-point F-FDG PET/CT in detecting colorectal carcinoma or advanced adenoma in patients with fixed focal colorectal F-FDG uptake.
Methods: A retrospective analysis was conducted on patients who underwent dual-time-point F-FDG PET/CT scans between January 2019 and December 2023.
Predicting malignant risk of ground-glass nodules using convolutional neural networks based on dual-time-point F-FDG PET/CT.
Cancer Imaging
February 2025
Department of Nuclear Medicine, The First Hospital of China Medical University, No. 155 Nanjing St, Shenyang, 110001, China.
Background: Accurately predicting the malignant risk of ground-glass nodules (GGOs) is crucial for precise treatment planning. This study aims to utilize convolutional neural networks based on dual-time-point F-FDG PET/CT to predict the malignant risk of GGOs.
Methods: Retrospectively analyzing 311 patients with 397 GGOs, this study identified 118 low-risk GGOs and 279 high-risk GGOs through pathology and follow-up according to the new WHO classification.